Cencora, Inc. (NYSE:COR) has reported a significant transaction involving its Chairman, President, and CEO, Steven H. Collis. According to the latest filing, Collis sold 10,754 shares of the company's common stock at an average price of $235.76, netting a total of over $2.5 million.
The transaction, which took place on June 18, 2024, was executed under a Rule 10b5-1 trading plan previously established on December 18, 2023, and disclosed in the company's Form 8-K filed with the SEC. Rule 10b5-1 trading plans allow company insiders to sell a predetermined number of shares at a predetermined time, providing a legal defense against potential accusations of insider trading by setting the trades up in advance.
In addition to the sale, the filing revealed that Collis also acquired 10,754 shares of Cencora's common stock on the same day through the exercise of options, at a price of $89.58 per share, amounting to a total of $963,343. These shares were part of a non-qualified stock option plan, with the options exercisable in four equal installments on specific dates from 2019 to 2022, as detailed in the footnotes of the SEC filing.
Following these transactions, Collis's ownership in the company stands at 285,088 shares of common stock directly held. The CEO's actions are part of the normal course of business for corporate executives, who often engage in stock transactions as part of their compensation and investment strategies.
Investors and market watchers frequently monitor insider buying and selling as it can provide insights into an executive's view of the company's future prospects. However, it is important to note that such transactions do not necessarily indicate a change in company fundamentals and can be influenced by various personal financial considerations.
Cencora, Inc., formerly known as AmerisourceBergen (NYSE:COR) Corp, operates in the wholesale drug distribution industry and is based in Conshohocken, Pennsylvania. The company's stock is listed on the New York Stock Exchange under the ticker symbol COR.
In other recent news, Cencora Inc. reported a healthy financial performance in its Q2 2024 earnings call. The company disclosed an 8% increase in revenue and a 9% rise in adjusted EPS. Furthermore, Cencora raised its adjusted operating income guidance for the full fiscal year, indicating a positive outlook on its growth trajectory. The company's investment in technology and data analytics, as well as a minority stake in OneOncology, underpins its commitment to enhancing its services and cancer care capabilities.
In addition to the earnings results, Baird, a global financial services firm, has increased its share price target for Cencora from $277 to $280. This adjustment was based on a combination of valuation methodologies, including price-to-earnings, discounted cash flow, and enterprise value to EBITDA analyses. The new target reflects Baird's confidence in Cencora's risk-adjusted growth prospects over the coming year.
These are among the recent developments for Cencora, which continues to navigate the complexities of the pharmaceutical industry while maintaining a focus on operational excellence.
InvestingPro Insights
As Cencora, Inc.'s (NYSE:COR) Steven H. Collis makes notable stock transactions, investors may find additional context in the company's financial metrics and market performance. According to InvestingPro, Cencora is trading at a high Price/Earnings (P/E) ratio of 25.57, indicating investor confidence in the company's future earnings potential. This is further supported by an adjusted P/E ratio for the last twelve months as of Q2 2024, which stands slightly lower at 22.62.
InvestingPro Tips suggest that Cencora's management has been proactively engaging in share buybacks, reflecting a potential belief in the stock's value. Furthermore, the company has a consistent track record of raising its dividend, having done so for 19 consecutive years, which may appeal to income-focused investors. These actions contribute to a narrative of a management team that is committed to returning value to shareholders.
On the performance front, Cencora has maintained a strong return over the last five years. This could resonate with investors looking for stability and growth in the healthcare providers and services industry. Additionally, the company's market capitalization stands at a robust $46.51 billion USD, underscoring its significant presence in the market.
For those seeking more in-depth analysis and additional InvestingPro Tips, you can explore https://www.investing.com/pro/COR. There are 18 additional tips listed on InvestingPro, offering a comprehensive view of Cencora's financial health and market position. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enriching your investment strategy with expert insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.